Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 9/20 | 0.50 |
| ▸ | RAB9A | P51151 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | MAOB | P27338 | 6/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5043403 | 0.89 | ACACB (0.52) | ACACBRAB9AMEN1KMT2ANPC1 | |
| SCHEMBL5048237 | 0.88 | ACACB (0.49) | ACACBRAB9AMEN1KMT2AMAOB | |
| Benzothiophene SCHEMBL20531230 | 0.85 | ACACB (0.40) | ACACBRAB9AMEN1KMT2ANPC1 | |
| SCHEMBL5043437 | 0.83 | ACACB (0.51) | ACACBRAB9AMEN1KMT2ANPC1 | |
| SCHEMBL5043428 | 0.83 | ACACB (0.49) | ACACBRAB9ANPC1MAOBMAOA | |
| SCHEMBL5046828 | 0.82 | ACACB (0.48) | ACACB | |
| SCHEMBL5043418 | 0.81 | ACACB (0.47) | ACACBMEN1KMT2AMAPTSMN1; SMN2 | |
| SCHEMBL5046911 | 0.78 | ACACB (0.53) | ACACB | |
| SCHEMBL5046813 | 0.78 | ACACB (0.55) | ACACBRAB9AKMT2ANPC1KDM4E | |
| SCHEMBL5046845 | 0.77 | ACACB (0.56) | ACACBRAB9ANPC1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7459480-B2 | Benzodioxepine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2008-12-02 | — | — | US | claimed |
| EP-1682528-B1 | BENZO [b][1,4] DIOXEPINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2007-09-12 | — | — | EP | claimed |
| US-20050113374-A1 | Benzodioxepine derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2005-05-26 | — | — | US | claimed |
| US-20250367263-A9 | Therapeutic Regimens and Methods for Treatment of Cardiovascular Risk Factors using a GLP-1R and GCGR Agonist | SPITFIRE PHARMA LLC (US) | 2025-12-04 | — | — | US | disclosed |
| US-20250288650-A1 | Therapeutic Regimens and Methods for Reducing Body Weight and/or Serum Lipids using a GLP-1R and GCGR Agonist | SPITFIRE PHARMA LLC (US) | 2025-09-18 | — | — | US | disclosed |
| US-20250281450-A1 | PEPTIDE PHARMACEUTICALS FOR TREATMENT OF NASH AND OTHER DISORDERS | MEDERIS DIABETES LLC (US) | 2025-09-11 | — | — | US | disclosed |
| EP-4611792-A1 | THERAPEUTIC REGIMENS AND METHODS FOR TREATMENT OF CARDIOVASCULAR RISK FACTORS USING A GLP-1R AND GCGR AGONIST | Spitfire Pharma LLC (US) | 2025-09-10 | — | — | EP | disclosed |
| US-20250262280-A1 | GLP-1R and GCGR Agonists, Formulations, and Methods of Use | SPITFIRE PHARMA LLC (US) | 2025-08-21 | — | — | US | disclosed |
| EP-4587045-A2 | THERAPEUTIC REGIMENS AND METHODS FOR REDUCING BODY WEIGHT IN A SUBJECT WITH FATTY LIVER DISEASE USING A GLP-1R AND GCGR AGONIST | Spitfire Pharma LLC (US) | 2025-07-23 | — | — | EP | disclosed |
| WO-2025129168-A1 | TRIAZOLONE INHIBITORS OF NICOTINAMIDE N-METHYLTRANSFERASE AND THEIR THERAPEUTIC USES | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2025-06-19 | — | — | WO | disclosed |
| US-20250134963-A1 | Therapeutic Regimens and Methods for Lowering Blood Glucose and/or Body Weight using GLP-1R and GCGR Balanced Agonists | SPITFIRE PHARMA LLC (US) | 2025-05-01 | — | — | US | disclosed |
| US-20200069770-A1 | TREATMENT OF AGE-RELATED MACULAR DEGENERATION AND OTHER EYE DISEASES WITH APOLIPOPROTEIN MIMETICS | MACREGEN, INC. (US) | 2020-03-05 | — | — | US | disclosed |
| US-10426817-B2 | Treatment of age-related macular degeneration and other eye diseases with apolipoprotein mimetics | MACREGEN, INC. (US) | 2019-10-01 | — | — | US | disclosed |
| US-20190015521-A1 | TOPICAL DELIVERY OF THERAPEUTIC AGENTS USING CELL-PENETRATING PEPTIDES FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION AND OTHER EYE DISEASES | MACREGEN, INC. | 2019-01-17 | — | — | US | disclosed |
| WO-2018236814-A2 | NICOTINAMIDE RIBOSIDE DERIVATIVES AND THEIR USES | GANAPATI GANGADHARA (US) | 2018-12-27 | — | — | WO | disclosed |
| US-20180362570-A1 | NICOTINAMIDE RIBOSIDE DERIVATIVES AND THEIR USES | MITOPOWER LLC | 2018-12-20 | — | — | US | disclosed |
| WO-2018161035-A1 | TREATMENT OF AGE-RELATED MACULAR DEGENERATION AND OTHER EYE DISEASES WITH ONE OR MORE THERAPEUTIC AGENTS | MACREGEN, INC. (US) | 2018-09-07 | — | — | WO | disclosed |
| US-20180207233-A1 | TREATMENT OF AGE-RELATED MACULAR DEGENERATION AND OTHER EYE DISEASES WITH APOLIPOPROTEIN MIMETICS | MACREGEN, INC. | 2018-07-26 | — | — | US | disclosed |
| US-7459480-B2 | Benzodioxepine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2008-12-02 | — | — | US | disclosed |
| US-20050113374-A1 | Benzodioxepine derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2005-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250288650-A1 | Therapeutic Regimens and Methods for Reducing Body Weight and/or Serum Lipids using a GLP-1R and GCGR Agonist | GLP1R, GCGR, GIPR | ACACB 763/4885RAB9A 1732/4885MEN1 1359/4885 |
| US-20250367263-A9 | Therapeutic Regimens and Methods for Treatment of Cardiovascular Risk Factors using a GLP-1R and GCGR Agonist | GLP1R, GCGR, GIPR | ACACB 1264/4885RAB9A 1322/4885MEN1 1818/4885 |
| US-20250134963-A1 | Therapeutic Regimens and Methods for Lowering Blood Glucose and/or Body Weight using GLP-1R and GCGR Balanced Agonists | GLP1R, GCGR, GIPR | ACACB 2195/4885RAB9A 1438/4885MEN1 1493/4885 |
| US-20180362570-A1 | NICOTINAMIDE RIBOSIDE DERIVATIVES AND THEIR USES | NME4, NADK, NQO1 | ACACB 719/4885RAB9A 734/4885MEN1 3915/4885 |
| US-20190015521-A1 | TOPICAL DELIVERY OF THERAPEUTIC AGENTS USING CELL-PENETRATING PEPTIDES FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION AND OTHER EYE DISEASES | NPC1L1, STARD3, CETP | ACACB 471/4885RAB9A 545/4885MEN1 3419/4885 |
| US-20250281450-A1 | PEPTIDE PHARMACEUTICALS FOR TREATMENT OF NASH AND OTHER DISORDERS | GLP1R, IAPP, GPR119 | ACACB 515/4885RAB9A 2361/4885MEN1 1281/4885 |
| US-20250262280-A1 | GLP-1R and GCGR Agonists, Formulations, and Methods of Use | GLP1R, GCGR, GPR119 | ACACB 1863/4885RAB9A 1501/4885MEN1 2065/4885 |
| US-20050113374-A1 | Benzodioxepine derivatives | BBOX1, ACOX1, ACOX3 | ACACB 5/4885RAB9A 3010/4885MEN1 3906/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.